AbbVie in Settlement With Generic Drugmakers on Rinvoq
PositiveHealth

AbbVie has reached a settlement with generic drugmakers regarding its drug Rinvoq, delaying U.S. generic entry until at least 2037.
Editor’s Note: This settlement is significant as it allows AbbVie to maintain its market exclusivity for Rinvoq, potentially leading to continued revenue growth and investment in further research and development.
— via World Pulse Now AI Editorial System